Grifols, S.A. American Depositary Receipt (GRFS)
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale
Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential upside to €20/share, driven by EPS growth and market expansion in plasma-derived products.
Grifols expects to boost revenue and free cash flow, shares soar
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost more than 30% of its market value.
Grifols' sales rise over 10% in 2024, above target
Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7% sales growth.
Mason Capital complains about Grifols' transparency to Spanish regulator
U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols.
Grifols: More Attractive Than In A Very Long Time
I don't divest unless the fundamental thesis changes; Grifols' buyout offer from Brookfield Asset Management is undervalued, so I maintain my "Buy" stance. Despite Brookfield's offer, I believe Grifols is worth more, as supported by recent 3Q24 results and the transaction committee's recommendation. The transaction committee advises against accepting the €10.5/share offer, aligning with my view that Grifols' real value is higher.
Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?
On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.
Grifols Stock Declines After Brookfield Drops Buyout Offer
Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.
Grifols shares tumble after report on Brookfield abandoning takeover plan
Shares in Grifols were falling on Wednesday morning after Bloomberg reported Canadian fund Brookfield is considering dropping its plan to take over the Spanish pharmaceutical firm.
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.
Grifols: Brookfields potential $6.8 bln offer undervalues the firm
Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential.
Grifols on track to meet 2024 targets despite third-quarter profit drop
Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago.
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down
Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage.
